Tests ST-01156 in people with advanced solid tumors
Tests a new drug, ST-01156, in adults with advanced solid tumors and certain cancers.
Plain-language title generated from the registry record
Registry title: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Key facts
- Where
- Boston, Duarte, Houston, New York, and Newport Beach, United StatesSee the 6 sites
- Phase
- Phase 1
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Mass General Brigham Cancer InstituteBoston, United StatesTaking people
- The City of Hope National Medical CenterDuarte, United StatesTaking people
- The University of Texas MD Anderson Cancer CenterHouston, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- Hoag Memorial HospitalNewport Beach, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- SEED Therapeutics, Inc.
- Trial code
- NCT07197554
- Record updated
- 27 October 2026
- Original description
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid MalignanciesRead full original descriptionShow less
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Inclusion: Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old; Has a metastatic or locally advanced and unresectable solid tumor; Has at least 1 measurable lesion or evaluable disease per RECIST v1.1; Has an ECOG performance status ≤ 2 at screening; Has adequate organ function as defined in the protocol.
Exclusion: Has received prior radiotherapy within 2 weeks of treatment; Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable; Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter; Had major surgery within 28 days before study therapy administration; Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy; Has previously received a RBM39 inhibitor/degrader.